The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use. Specifically, this RFP focuses on developing novel PET ligands for clinical trials, supporting novel CSF biomarkers, validating innovative MRI approaches in larger cohorts, and more. Must be received by...